Search results
Learn how likely it is that people with ovarian or fallopian tube cancer will live for 5 years after diagnosis, based on how far the cancer has spread. See the 5-year relative survival rates for different types and stages of ovarian cancer, and how they vary over time.
- Ovarian Cancer Stages
The stage of a cancer describes how much cancer is in the...
- Signs and Symptoms of Ovarian Cancer
Ovarian cancer may cause several signs and symptoms. Women...
- Questions To Ask Your Doctor
When diagnosed with ovarian cancer, learn which questions...
- Tests for Ovarian Cancer
If your doctor finds something suspicious during a pelvic...
- Ovarian Cancer Screening
Many women with ovarian cancer have high levels of CA-125....
- Targeted Drug Therapy for Ovarian Cancer
This drug can be used to treat epithelial ovarian cancer...
- Causes, Risk Factors, and Prevention
Ovarian Cancer Causes, Risk Factors, and Prevention. Learn...
- Radiation Therapy for Ovarian Cancer
Aggressive chemotherapy is usually more effective, so...
- Ovarian Cancer Stages
Survival for all stages of ovarian cancer. For women with ovarian cancer in England: more than 70 out of 100 women (more than 70%) will survive their cancer for 1 year or more after they are diagnosed. 45 out of 100 women (45%) will survive their cancer for 5 years or more.
Stage at diagnosis is a strong predictor of ovarian cancer survival, but tumour histotype and grade remain predictors of survival even after adjustment for stage and other factors, contributing further evidence of biological dissimilarity between the ovarian cancer histotypes.
6 wrz 2022 · Learn how ovarian cancer is hard to detect, but new and improved treatments are increasing survival. Find out about surgery, chemotherapy, targeted therapy, fertility preservation and clinical trials for ovarian cancer.
Tematy dnia
Learn about the 5-year survival rates for different types and stages of ovarian cancer, based on data from the SEER registry. Find out how staging, tumor type, and treatment affect your outlook and what factors can influence your prognosis.
Niraparib first-line maintenance significantly prolonged progression-free survival (PFS) among patients with newly diagnosed advanced ovarian cancer that responded to first-line platinum-based chemotherapy, regardless of homologous recombination deficiency (HRD) status.
1 gru 2022 · Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after diagnosis, but those who have an exceptionally long...